Evidence map›Paper›PMID 40130092›Full record

ReviewCureus2025

The Future of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Gene Therapy in Cardiomyopathies: A Review of Its Therapeutic Potential and Emerging Applications.

Ali Moradi, Sina Khoshniyat, Tochukwu Nzeako, Mohammad Amin Khazeei Tabari, Olawale O Olanisa, Kutiba Tabbaa, Hamza Alkowati, Melika Askarianfard, Daoud Daoud, Olu Oyesanmi and 2 more

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Heart Failure in Hypertrophic Cardiomyopathy.Cardiac failure review · 2026
    Review
  3. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  4. Gene- and cell-based therapy in cardiovascular diseases.Journal of cardiovascular pharmacology · 2025
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ali MoradiInternal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Sina KhoshniyatBiomedicine, School of Sciences, La Trobe University, Melbourne, AUS.
Tochukwu NzeakoInternal Medicine, Christiana Hospital, Newark, USA.
Mohammad Amin Khazeei TabariMedicine, Mazandaran University of Medical Sciences, Sari, IRN.
Olawale O OlanisaInternal Medicine, Trinity Health Grand Rapids, Grand Rapids, USA.
Kutiba TabbaaCardiology, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Hamza AlkowatiInternal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Melika AskarianfardMedicine, Marmara University, Istanbul, TUR.
Daoud DaoudInternal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Olu OyesanmiInternal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Angelina RodriguezFamily Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.
Yizhi LinInternal Medicine, HCA Florida Blake Hospital, University of South Florida (USF) Morsani College of Medicine, Bradenton, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiomyopathies, among the leading causes of heart failure and sudden cardiac death, are often driven by genetic mutations affecting the heart's structural proteins. Despite significant advancements in understanding the genetic basis of hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC), effective long-term therapies remain limited. The advent of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene editing offers a promising therapeutic strategy to address these genetic disorders at their root. CRISPR-Cas9 enables precise modification of pathogenic variants (PVs) in genes encoding sarcomeric and desmosomal proteins, which are frequently implicated in cardiomyopathies. By inducing site-specific double-stranded breaks in DNA, followed by repair through nonhomologous end joining (NHEJ) or homology-directed repair (HDR), this system allows for targeted correction of mutations. In preclinical models, CRISPR-Cas9 has shown promise in correcting HCM-associated mutations in β-myosin heavy chain 7 (MYH7), preventing disease phenotypes such as ventricular hypertrophy and myocardial fibrosis. Similarly, gene editing has successfully rectified DCM-linked mutations in Titin (TTN) and LMNA, resulting in improved heart function and reduced pathological remodeling. For ARVC, CRISPR-Cas9 has demonstrated the ability to repair mutations in desmosomal genes such as plakophilin 2 (PKP2), thereby restoring normal cardiac function and cellular adhesion. Despite these successes, challenges remain, including mosaicism, delivery efficiency, and off-target effects. Nevertheless, CRISPR-Cas9 represents a transformative approach to treating genetic cardiomyopathies, potentially offering long-lasting cures by directly addressing their underlying genetic causes.

Indexed as

arrhythmogenic right ventricular cardiomyopathy (arvc/d)cardiomyopathycrisprcrispr cascrispr/cas9 gene editingcrispr-cas9-mediated gene editingdilated cardiomyopthyhcmhypertrophy cardiomyopathy

Identifiers

PMID40130092
PMCPMC11930791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.